โ Scribed by Shayne Cox Gad
No coin nor oath required. For personal study only.
Drug Safety EvaluationSecond EditionShayne Cox GadThe updated and expanded safety guide to all aspects of the drug development processDrug Safety Evaluation, Second Edition presents an all-inclusive, practical guide for those who are responsible for ensuring the safety of drugs and biologics for patients, for health care providers, for those involved in the manufacture of medicinal products, and for all those who need to understand how the safety of these products is evaluated. This Second Edition has been extensively revised and expanded to respond to the many changes in regulatory requirements as well as pharmaceutical and technological developments. Drawing upon more than twenty years of experience, author Shayne Gad explains the scientific and philosophical bases for evaluating specific concerns (e.g., cardiovascular safety, immunogenicity, carcinogenicity, development toxicity, etc.) to provide both understanding and guidance for approaching new problems. Individual chapters address not only the general cases for safety evaluation of small and large molecules, but also all the significant major sub-cases: imaging agents, dermal and inhalation route drugs, vaccines, and gene-therapy products. Among the wide variety of topics covered are: Acute toxicity testing in pharmaceutical safety evaluation Genotoxicity Safety assessment of inhalant drugs Immunotoxicology in pharmaceutical development Large animal studies Evaluation of human tolerance and safety in clinical trialsMore pertinent and practical than ever to the industry, Drug Safety Evaluation, Second Edition provides a road map for safety assessment as an integral part of the development of new drugs and therapeutics.
Drug Safety Evaluation......Page 3
Contents......Page 9
Preface......Page 11
Acknowledgment......Page 12
About the Author......Page 13
1. Drug Development Process and Global Pharmaceutical Marketplace......Page 15
2. Regulation of Human Pharmaceutical Safety......Page 33
3. Prior Art and Its Use in Safety Assessment Process......Page 103
4. Screens in Safety and Hazard Assessment......Page 117
5. Formulations, Routes, and Dosage Design......Page 135
6. Single-Dose (Acute) and Pilot (DRF) Toxicity Testing in Drug Safety Evaluation......Page 199
7. Genotoxicity......Page 248
8. Repeat-Dose Toxicity Studies......Page 318
9. Immunotoxicology in Drug Development......Page 340
10. Nonrodent Animal Studies......Page 414
11. Developmental and Reproductive Toxicity Testing......Page 455
12. Carcinogenicity Studies......Page 495
13. Histopathology in Nonclinical Pharmaceutical Safety Assessment......Page 534
14. Irritation and Local Tissue Tolerance in Pharmaceutical Safety Assessment......Page 545
15. Pharmacokinetics and Toxicokinetics in Drug Safety Evaluation......Page 582
16. Safety Pharmacology......Page 633
17. Special Concerns for Preclinical Evaluation of Biotechnology Products......Page 658
18. Safety Assessment of Inhalant and Dermal Route Drugs......Page 702
19. Special-Case Products: Imaging Agents and Oncology Drugs......Page 739
20. Occupational Toxicology in Pharmaceutical Industry......Page 751
21. Strategy and Phasing for Nonclinical Drug Safety Evaluation in Discovery and Development of Pharmaceuticals......Page 773
22. Application of In Vitro Techniques in Drug Safety Assessment......Page 802
23. Evaluation of Human Tolerance and Safety in Clinical Trials: FIM Trials and Beyond......Page 875
24. Postmarketing Safety Evaluation: Monitoring, Assessing, and Reporting of Adverse Drug Responses......Page 949
25. Statistics in Pharmaceutical Safety Assessment......Page 986
26. Combination Products: Drugs and Devices......Page 1097
27. Qualification of Impurities, Degradants, Residual Solvents, and Leachables in Pharmaceuticals......Page 1114
Appendix A. Selected Regulatory and Toxicological Acronyms......Page 1131
Appendix B. Definition of Terms and Lexicon of Clinical Observations in Nonclinical (Animal) Studies......Page 1135
Appendix C. Notable Regulatory Internet Addresses......Page 1139
Appendix D. Glossary of Terms Used in Clinical Evaluation of Therapeutic Agents......Page 1147
Appendix E. Common Vehicles for Nonclinical Evaluation of Therapeutic Agents......Page 1154
Appendix F. Global Directory of Contract Toxicology Laboratories......Page 1175
Index......Page 1185
๐ SIMILAR VOLUMES
"Contains an entirely new chapter on U.S., EEC, and Japanese regulatory matters, and topical information on combination equipment, contract testing labs, and Internet sites."
Drug Safety Evaluation presents an all-inclusive, practical guide for those who are responsible for ensuring the safety of drugs and biologics for patients, for health care providers, for those involved in the manufacture of medicinal products, and for all those who need to understand how the safety
Strategy and phasing for drug safety evaluation in the discovery and development of pharmaceuticals -- Regulation of human pharmaceutical safety -- Information sources: Building and maintaining data files -- screens in safety and hazard assessment -- Acute toxicity testing in drug safety evaluation
<span>Drug Safety Evluation</span><p><span>Comprehensive and practical guide presenting a roadmap for safety assessment as an integral part of the development of drugs and therapeutics</span></p><p><span> This fourth edition of </span><span>Drug Safety Evaluation </span><span>maintains the central o
Gad brings some 25 years of experience in toxicology, drug development, and risk assessment to this practical guide for those in the pharmaceutical and biotechnology industries responsible for ensuring the safety of drugs and biologics to patients, health care providers, manufacturers of medicinal p